Today: 5 February 2026
Subscribe
Browse Category

Biotech News News 5 January 2026 - 9 January 2026

Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week

Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week

New York, Jan 9, 2026, 14:36 (EST) — Regular session Nuvation Bio Inc (NUVB) shares slid about 4.7% to $8.05 Friday afternoon, after earlier hitting a session low of $8.05. The stock’s pullback follows new sell-side takes on a name that’s been re-rated since shifting into the commercial stage. UBS started coverage at Neutral with a $10 price target. RBC,…
9 January 2026
···
Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens

Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens

New York, January 8, 2026, 14:40 EST — Regular session Arcus Biosciences (RCUS) shares slid 9.3% to $21.05 in afternoon trading on Thursday, after earlier touching $22.70. The stock hit a session low of $21.02. Morgan Stanley cut its rating on Arcus to “equal weight” from “overweight” and trimmed its price target to $20 from $23, Investing.com reported, calling the…
8 January 2026
·····
Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

NEW YORK, Jan 8, 2026, 08:59 (EST) — Premarket Omeros Corp (OMER.O) shares were up 0.55, or about 4%, at $14.09 in premarket trade on Thursday after the drugmaker set a $36,000 price for each single-dose vial of its newly approved Yartemlea treatment for transplant-associated thrombotic microangiopathy (TA-TMA). “Median utilization was 8 to 10 vials per treatment course,” Chief Executive…
8 January 2026
·····
Legend Biotech (LEGN) stock jumps after Oppenheimer starts coverage with $75 target

Legend Biotech (LEGN) stock jumps after Oppenheimer starts coverage with $75 target

New York, January 7, 2026, 12:32 (EST) — Regular session Shares of Legend Biotech Corp rose 7.4% to $22.53 in midday trading on Wednesday after Oppenheimer initiated coverage with an “Outperform” rating and set a $75 price target, according to MarketBeat. StreetInsider said Oppenheimer analyst Trevor Allred authored the initiation note. MarketBeat Why it matters now: Legend’s stock has been…
7 January 2026
·····
Abivax stock jumps 7% on Nasdaq — here’s what’s moving ABVX and what’s next

Abivax stock jumps 7% on Nasdaq — here’s what’s moving ABVX and what’s next

New York, Jan 7, 2026, 11:10 EST — Regular session Shares of Abivax SA jumped 7.3% to $127.75 in morning trading on Wednesday, after touching a session high of $128.87 and a low of $119.48. Trading volume topped 700,000 shares. The French biotech’s U.S.-listed stock has become a fast-moving name for healthcare traders, in part because its valuation rests on…
7 January 2026
·····
Ventyx Biosciences stock jumps premarket as Eli Lilly buyout talks fuel takeover buzz

Ventyx Biosciences stock jumps premarket as Eli Lilly buyout talks fuel takeover buzz

New York, Jan 7, 2026, 05:03 EST — Premarket Ventyx Biosciences shares jumped about 66% before the bell on Wednesday after a report that Eli Lilly is in advanced talks to buy the biotech company for more than $1 billion. The stock traded at $16.70 in premarket action, versus a $10.05 regular-session close. Public The move matters because a confirmed…
7 January 2026
······
Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

New York, January 6, 2026, 15:27 (ET) — Regular session Nasdaq-listed Travere Therapeutics shares fell 5.3% to $36.09 in afternoon trading on Tuesday as investors looked toward next week’s U.S. FDA decision deadline on expanding its kidney drug Filspari (sparsentan) into focal segmental glomerulosclerosis. The FDA’s Prescription Drug User Fee Act, or PDUFA, target action date is Jan. 13, and…
6 January 2026
·····
Johnson & Johnson stock ticks up on lupus drug data as earnings loom

Johnson & Johnson stock ticks up on lupus drug data as earnings loom

New York, January 6, 2026, 12:58 EST — Regular session Johnson & Johnson (JNJ.N) shares rose on Tuesday after the company reported positive mid-stage data for its experimental lupus drug nipocalimab and outlined plans for late-stage testing. The stock was up $1.10, or 0.5%, at $205.41 in midday New York trading. The update puts fresh focus on J&J’s drug pipeline…
6 January 2026
·····
Immunome (IMNM) stock drops 5% as biotech slips; investors look to Jan. 14 update

Immunome (IMNM) stock drops 5% as biotech slips; investors look to Jan. 14 update

NEW YORK, Jan 5, 2026, 15:54 EST — Regular session Shares of Immunome, Inc. fell 5.3% to $19.72 in late afternoon trading on Monday, underperforming U.S. biotech peers. The SPDR S&P Biotech ETF slid 1.1% and the iShares Nasdaq Biotechnology ETF was off 0.9%. IMNM opened at $20.83 and touched $19.36, with about 1.6 million shares changing hands by 3:54…
5 January 2026
·····
Argenx stock slides 5% on CEO handover plan — what investors watch next

Argenx stock slides 5% on CEO handover plan — what investors watch next

New York, Jan 5, 2026, 15:30 EST — Regular session Shares of argenx fell about 5% on Monday after the immunology drugmaker said Chief Operating Officer Karen Massey will succeed co-founder Tim Van Hauwermeiren as CEO, with Van Hauwermeiren set to become board chairman pending a shareholder vote on May 6. The stock was down 5% at $797.94 in afternoon…
5 January 2026
····
Spyre Therapeutics stock drops as biotech slides — what SYRE investors watch next

Spyre Therapeutics stock drops as biotech slides — what SYRE investors watch next

New York, January 5, 2026, 15:09 EST — Regular session Shares of Spyre Therapeutics Inc fell 2.7% to $29.75 in afternoon trading on Monday, extending a choppy start to the year for smaller biotechnology names. The stock traded between $28.02 and $30.75, with about 0.63 million shares changing hands. The decline tracked weakness across the biotech complex, with the SPDR…
5 January 2026
····
Wave Life Sciences stock drops 8% as JPM Healthcare Conference looms; obesity data in focus

Wave Life Sciences stock drops 8% as JPM Healthcare Conference looms; obesity data in focus

New York, January 5, 2026, 1:09 PM ET — Regular session Wave Life Sciences Ltd shares fell $1.34, or 8.4%, to $14.61 in afternoon trade on Monday, extending a sharp pullback in the clinical-stage biotech even as the company flagged an investor-conference appearance next week. The move matters because the J.P. Morgan Healthcare Conference often sets the tone for biotech…
5 January 2026
····
1 2 3 4 5 6 … 12

Stock Market Today

  • Software Stocks Falter as Google Boosts AI Spend; Layoffs Surge Ahead of Delayed Jobs Report
    February 5, 2026, 9:21 AM EST. Software stocks face renewed pressure amid skepticism about the sector's trajectory as artificial intelligence expands in enterprise. Alphabet, Google's parent, surpassed Q4 expectations but warned of capital expenditures potentially doubling in 2026 to support AI infrastructure, triggering a 4% drop in premarket shares. Meanwhile, AI suppliers like Broadcom saw gains. Labor market signals dim with delayed U.S. job reports, recent private sector hiring falling short, and January layoffs surging by over 200% from December, the highest for the month since 2009. Oil prices climbed 1.5% in Asia over fears of a U.S. strike on Iran potentially disrupting supply.
Go toTop